Abiraterone for De Novo mHSPC Less Beneficial at Age 70+

Men aged 70 years or older with de novo mHSPC derive less benefit from abiraterone plus prednisone added to standard of care.

Related Keywords

California ,United States ,France ,San Francisco ,American ,Loic Mourey ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Cancers Symposium ,Linstitut Universitaire ,